A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)

Trial Profile

A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms RV-MDS-PI0550REV-AZA
  • Sponsors Celgene International SARL
  • Most Recent Events

    • 08 Dec 2015 Status changed from recruiting to active, no longer recruiting, as per an abstract presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Jun 2015 Preliminary results (n=44) presented at the 20th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top